

DAFTAR PUSTAKA

1. Ivovic V, Potusek S, Buzan E. Prevalence and genotype identification of *Toxoplasma gondii* in suburban rodents collected at waste disposal sites. *Parasite*. 2019;26:27.
2. Iskandar A, Mayashinta DK, Sudjari, Indra MR. Mengenal *Toxoplasma gondii*, obesitas dan sindrom metabolik. ed ke 1. Malang: UB Press; 2018:8-9
3. Aslam MS, Naveed S, Ahmed A, Abbas Z, Gull I, Athar MA. Side effects of chemotherapy in cancer patients and evaluation of patients opinion about starvation based differential chemotherapy. *Journal of Cancer Therapy*. 2014;05(08):817–22.
4. Cong W, Liu GH, Meng QF, Dong W, Qin SY, Zhang FK, et al. *Toxoplasma gondii* infection in cancer patients: prevalence, risk factors, genotypes and association with clinical diagnosis. *Cancer Lett.* 2015;359(2):307–13.
5. Sullivan WJ, Victoria J. Mechanisms of *Toxoplasma gondii* persistence and latency. *FEMS Microbiol Rev*. 2011;23(1):1–7.
6. Nurgali K, Jagoe RT, Abalo R. Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? *Front Pharmacol*. 2018;9:1–3.
7. Nasrul EY. Gambaran *Toxoplasma gondii* pada feses kucing di kecamatan padang utara kota padang (skripsi). Fakultas Kedokteran Universitas Andalas. 2015:3
8. Hamid DM: Prevalance of toxoplasmosis among cancer patients. *Int. J. Adv. Res*. 2017;5(7):1362–6.
9. Halonen S, Weiss L. Toxoplasmosis. *Handb clin Neurol*. *Handb clin Neurol*. 2014. 125–145.
10. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. *Cancer*. 2004;100(2):228–37.
11. Lustberg MB. Management of neutropenia in cancer patients. *Clin Adv Hematol Oncol*. 2012;10(12):825–6.
12. American Cancer Society. Cancer treatments can increase infection risk. 2015 [cited 2019 Oct 4]. Available from: <https://www.cancer.org/content/cancer/en/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/infections-in-people-with-cancer/how-treatment-increases-risk.html>
13. Martin LJ. How chemotherapy affects the immune system. WebMD. 2014 [cited 2019

- Oct 4]. Available from: <https://www.breastcancer.org/tips/immune/cancer/chemo>
14. Pardoll D. Cancer and the immune system: basic concepts and targets for intervention. *Semin Oncol.* 2017;42(4):523–38. 15.
 15. Solomeyer EF, Feuerer M, Bai L, Umansky V, Beckhove P, Meyberg GC, et al. Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. *Clin Cancer Res.* 2003 Jan;174-80.
 16. Yaman O, Altuntas F. Investigation of anti-*Toxoplasma gondii* antibodies in patients with neoplasia. *J Med Microbiol.* 2004;53(May):1183–6.
 17. Mehrdad G, Sharif M, Jasem S, Mohammad P. Determination of antibodies (IgG, IgM) against *Toxoplasma gondii* in patients with cancer. *Orig Artic.* 2007;2(4):1–6.
 18. Texas Oncology. October is breast cancer awareness month: low white blood count. *Texas Oncology.* Diakses 14 Oktober 2019.
 19. McAuley JB. Congenital toxoplasmosis. *J Pediatric Infect Dis Soc.* 2014;3:30–5.
 20. Morrison DA, Höglund J. Testing the hypothesis of recent population expansions in nematode parasites of human-associated hosts. *Heredity (Edinb).* 2005;94(4):426–34.
 21. Remington JS, McLeod R, Thulliez P, Desmonts G. Toxoplasmosis. infectious diseases of the fetus and newborn infant. *Arch Dis Child Fetal Neonatal Ed.* 2006;6:947-1091.
 22. Tenter AM, Heckeroth AR, Weiss LM. *Toxoplasma gondii*: from animals to humans. *Int J Parasitol.* 2000;30(12–13):1217–58.
 23. Chaudhry SA, Gad N, Koren G. Toxoplasmosis and pregnancy. *Can Fam Physician.* 2014;60(4):334–336.
 24. Frenkel JK. Pathophysiology of toxoplasmosis. *Parasitol Today.* 1988;4(I):273–8.
 25. Bhopale GM. Pathogenesis of toxoplasmosis. *Comp. Immun. Microbiol. Infect. Dis.* 2003;26:213–22.
 26. Choi CW, Sung HJ, Park KH, Yoon SY, Kim SJ, Oh SC, et al. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. *Am J Hematol.* 2003;266(April):263–6.
 27. Soedarto. Masalah titer IgG dan IgM dalam menentukan diagnosis toksoplasmosis. *Jurnal Ilmiah Kedokteran Wijaya Kusuma.* 2017;(2):1–5.
 28. Dubey JP, Lindsay DS, Speer CA. Structures of *Toxoplasma gondii* tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. *Clin Microbiol Rev.* 1998;11:267-299.

29. Bliss SK, Gavrilescu LC, Alcaraz ANA. Neutrophil depletion during *Toxoplasma gondii* infection leads to impaired immunity and lethal systemic pathology. Infect Immun. 2001;69(8):4898–905.
30. Shibutani M, Maeda K, Nagahara H, et al. Lymphopenia associated with adjuvant chemotherapy after potentially curative surgery for colorectal cancer correlates with recurrence. International surgery . 2016:19-22.
31. Denkers EY, Butcher BA, Rio L Del, Bennouna S. Neutrophils, dendritic cells and toxoplasma. Int J Parasitol. 2004;34:411–21.
32. Ali MI, Abd El Wahab WM, Hamdy DA, Hassan A. *Toxoplasma gondii* in cancer patients receiving chemotherapy: seroprevalence and interferon gamma level. J Parasit Dis [Internet]. 2019;43(3):464–71.
33. Wang FEN, Liu Z, Xia Y, Zhou C, Shen X. Changes in neutrophil / lymphocyte and platelet / lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer. 2015;3411–8.
34. Waluyo A. Analisis masalah keperawatan pada klien keganasan hematologi yang mendapatkan terapi medik kemoterapi. J Keperawatan Indonesi. 2008;8(1):1-7.
35. Nimir A. Latent toxoplasmosis in patients with different malignancy: A hospital based study. J Clin Med Res. 2010;2(3):117–20.
36. Bajnok J, Tarabulsi M, Carlin H, Bown K, Southworth T, Dungwa J, et al. High frequency of infection of lung cancer patients with the parasite *Toxoplasma gondii* . ERJ Open Res. 2019;5(2):00143–2018.
37. Baiomy AM, Mohamed KA, Ghannam MA, Shahat SA, Al-Saadawy AS. Opportunistic parasitic infections among immunocompromised Egyptian patients. J Egypt Soc Parasitol. 2010;40(3):797-808.
38. Duan Y, Zhi Y, Liu Y, Zhou N, Li F, Hao X, et al. *Toxoplasma gondii* infection in children with lymphoma in Eastern China: seroprevalence, risk factors and case-control studies. Epidemiol Infect. 2019;147:e305.
39. Hong CW. Current understanding in neutrophil differentiation and heterogeneity. Immune Netw. 2017;17(5):298–306.
40. Gigley JP, Bhadra R, Khan IA. CD8 T cells and toxoplasma gondii: A new paradigm. J Parasitol Res. 2011.
41. McLeod R, Estes RG. Role of lymphocyte blastogenesis of *Toxoplasma gondii* antigens in containment of chronic, latent *T. gondii* infection in humans. Clin Exp Immunol.

1985;62(1):24–30.

42. Dupont CD, Christian DA, Hunter CA. Immune response and immunopathology during toxoplasmosis. 2013;34:793–813.

